Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

NCT03287245 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03287245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03287245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Terminated
Start date
February 21, 2018
Completion date
March 3, 2020
Enrollment
27 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera